Accendra Health

Moat components and our scores: Intangible assets 55/100 (national brands Apria and Byram but limited brand loyalty in insurer-driven channels). Switching costs 60/100 (payer contracts, referral relationships and documentation workflows create moderate friction; individual patient switching remains feasible).

Network effects 20/100 (limited true two-sided network dynamics). Cost advantages 65/100 (scale purchasing, vendor rebates, national logistics and in-home clinical coverage help on unit costs). Efficient scale 55/100 (local market density matters, although competitors such as AdaptHealth and Lincare also have scale).

Overall moat is a blend of payer-process stickiness and scale rather than customer love, and it can erode if service levels slip or payers rebid volumes aggressively. The large 2025 payer contract termination underscores fragility.

Direct pricing power is constrained by Medicare, Medicaid and commercial payer schedules. Margin improvement typically comes from mix, documentation rigor, resupply adherence and operations rather than list price increases. The company’s own disclosures emphasize reimbursement dependency and competitive bidding risk across DMEPOS categories.

We see limited latent pricing power beyond what mix and productivity can yield.

Category demand is structurally recurring, tied to chronic conditions and resupply programs, which usually supports steady cash generation.

However, payer concentration and the recent termination equal to ~12 percent of 2025 revenue add a period of elevated variance through at least mid-2026. We model mid single-digit organic revenue growth once churn stabilizes, but near-term quarter-to-quarter will remain choppy as payer transitions complete.

Leverage is the core weakness. As of March 31, 2026, total debt was ~2.10 billion, cash ~337 million and net debt ~1.77 billion. TTM adjusted EBITDA is roughly 337 million, implying net leverage of ~5.2x. Q1 2026 interest expense was ~32 million, or ~125 to 130 million run-rate, resulting in modest interest coverage.

The announced optimization extends maturities and may reduce funded debt by up to ~115 million, but coupons step up to 9.00 percent to 9.75 percent on new secured notes, keeping interest burden meaningful.

Positives: management executed a strategic separation, focusing the company on higher-margin Patient Direct with improving cash conversion. Negatives: 2025 included an 80 million break fee for the terminated Rotech deal, and leverage remains elevated, constraining optionality for repurchases or significant M&A.

Near-term priorities are deleveraging, service quality and stable payer terms. We view this as rational but not yet a compounding playbook.

CEO Edward Pesicka and team have steered a complex carve-out and are addressing the capital structure proactively. Governance looks conventional and large long-term holders such as Coliseum are engaged, which can support discipline.

Execution risk remains around payer transitions and operational service, as public consumer sentiment on Apria is mixed and will require sustained process improvement.